At a glance
- Originator Dainippon Sumitomo Pharma
- Class Anti-inflammatories
- Mechanism of Action Chymase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Skin disorders
Most Recent Events
- 18 Oct 2005 No development reported - Preclinical for Skin disorders in Japan (unspecified route)
- 01 Oct 2005 Sumitomo Pharmaceuticals has merged with Dainippon Pharmaceutical to form Dainippon Sumitomo Pharma
- 26 Apr 2002 Preclinical trials in Skin disorders in Japan (unspecified route)